Elevance Health (ELV) Holds Steady Despite Medicaid Headwinds and Targeted Exits

Elevance Health Inc. (NYSE: ELV) delivered strong second-quarter results and raised its full-year earnings outlook on July 15, but investor confidence remains cautious amid ongoing Medicaid challenges.

Q2 Earnings Beat and Guidance Raise

In its Q2 2026 earnings report, Elevance posted operating revenue of $49.8 billion and an adjusted diluted EPS of $7.45, both exceeding internal expectations. The company raised its full-year adjusted EPS guidance to at least $27 and operating cash flow guidance to at least $6 billion. These figures were supported by disciplined execution across its Health Benefits and Carelon businesses and a favorable non-recurring benefit of about $0.80 per share. The third-quarter dividend of $1.72 per share is set to be paid on September 25 to shareholders of record as of September 10.

Medicaid Margin Pressures and Market Exits

Despite the earnings beat, Medicaid remains a significant pressure point. Management indicated the business is in a “margin trough” for 2026 but expects gradual improvement through rate alignment and care management reforms. However, cost trends remain elevated, driven largely by behavioral health, specialty drug spending, outpatient surgeries, and ER utilization. As a result, Elevance plans to exit Washington, D.C.’s Medicaid market immediately and additional underperforming markets over the next 12 to 18 months.

Stock Reaction Reflects Concerns Over Forward Momentum

Even with raised forecasts, shares fell sharply by more than 11% following the earnings announcement—indicating that investor expectations may have been higher. Analysts and investors appear particularly focused on the sustainability of margin recovery and the return trajectory of Medicaid operations.

Takeaway

Elevance Health’s Q2 results and raised guidance offer a positive baseline, supported by operational discipline and strength in non-Medicaid segments. Yet ongoing Medicaid margin pressures and strategic withdrawal from certain markets underscore significant risks ahead. As 2027 performance hinges on Medicaid stabilization and broader healthcare cost trends, investors will be closely watching the company’s execution of its margin recovery strategy.